Advertisement

Clinical and metabolic effects of pentaerythritol tetranicotinate (perycit®) and a comparison with plain nicotinic acid

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Perycit in a daily dose of 3 g lowers the cholesterol and triglyceride concentration in patients with different types of hyperlipidemia. Increasing the Perycitl® dose up to 4.5 g causes a further decrease of the lipid levels. A comparison between Perycit® and pure nicotinic acid showed that Perycit® in doses up to 6 g is more effective in reducing elevated cholesterol levels. The reduction of the plasma triglyceride and cholesterol concentration is explained by a decrease of VLD triglyceride and cholesterol concentration. The cholesterol concentration also decreased in the LD fraction but increased in the HD fraction. The K2 of the i.v. fat tolerance was not significantly influenced by the Perycit® treatment in the material studied and changes of the triglyceride concentration were not related to changes in K2, suggesting that the mechanism of action of Perycit® on the plasma lipids differs at least partly from that of pure nicotinic acid. As with nicotinic acid, elevated levels of transaminase and alkaline phosphatases were observed with Perycit® but the increases were not related to the dose used or to the duration of the treatment. Perycit®, in contrast to pure nicotinic acid, did not elevate the uric acid concentration in plasma.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Altschul R.
        • Hoffer A.
        • Stephen J.D.
        Influence of nicotinic acid on serum cholesterol in man.
        Arch. Biochem. 1955; 54: 558
        • Altschul R.
        Altschul R. Niacin in Vascular Disorders and Hyperlipemia. Charles C. Thomas, Springfield, Ill1964
        • Carlson L.A.
        The effect of nicotinic acid treatment on the chemical composition of plasma lipoprotein classes in man.
        in: Drugs Affecting Lipid Metabolism, Advances in Experimental Medicine and Biology. Vol. 4. Plenum Press, New York, N.Y1969: 327
        • Carlson L.A.
        • Orö L.
        Behandling med nikotinsyra, II (Kliniska erfarenheter).
        in: Symposium: Synpunkter på behandling med höga doser nikotinsyra. Läkartidningen. 63. 1966: 4281
        • Carlson L.A.
        • Orö L.
        • Östman J.
        Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia.
        Acta Med. Scand. 1968; 183: 457
        • Carlson L.A.
        • Orö L.
        • Östman J.
        Effect of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia during the first week of treatment.
        J. Atheroscler. Res. 1968; 8: 667
        • Carlson L.A.
        • Orö L.
        The effect of nicotinic acid on the plasma free fatty acids. Demonstration of a metabolic type of sympathicolysis.
        Acta Med. Scand. 1962; 172: 641
        • Orö L.
        Indikationer for nikotinsyra och nikotinsyrederivat.
        Läkartidningen. 1970; 67: 63
        • Brattsand R.
        • Lundholm L.
        The effect of nicotinic acid and pentaerythritol-tetranicotinate upon experimental atherosclerosis in the rabbit.
        Atherosclerosis. 1971; 14: 91
        • Brox D.
        • Selvaag O.
        The effect of erythritol-tetra-nicotinate on serumcholesterol levels in man.
        Acta Med. Scand. 1967; 182: 437
        • Harthon L.
        • et al.
        Influence of nicotinic acid derivatives NAD+ levels of blood, liver, adipose tissue and aorta during hyperlipemic conditions.
        in: Gey K.F. Carlson L.A. Metabolic Effects of Nicotinic Acid and its Derivatives. Hans Huber, Bern1971: 115
        • Lundholm L.
        Nikotinsyra och dess derivats lipidsänkande effekt.
        Läkartidningen. 1971; 68: 1746
        • Ribom U.
        Nikotinsyraterapi.
        Läkartidningen. 1971; 68: 1750
        • Sigroth K.
        Pentaerythritoltetranicotinate (Perycit®) in the treatment of hypercholesterolaemia.
        Acta Med. Scand. 1968; 184: 269
        • Svedmyr N.
        • et al.
        Dose response relationship between concentration of free nicotinic acid concentration of plasma and some metabolic and circulatory effects after administration of nicotinic acid and pentaerythritoltetranicotinate in man.
        in: Gey K.F. Carlson L.A. Metabolic Effects of Nicotinic Acid and its Derivatives. Hans Huber, Bern1971: 1085
        • Svedmyr N.
        • Harthon L.
        Comparison between the absorption of nicotinic acid and pentaerythritoltetranicotinate (Perycit®) from ordinary enterocoated tablets.
        Acta Pharmacol. (Kbh). 1970; 28: 66
        • Hatch F.T.
        • Lees R.S.
        Practical methods for plasmalipoprotein analysis.
        Advan. Lipid Res. 1968; 6: 1
        • Carlson L.A.
        • Orö L.
        Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia.
        Atherosclerosis. 1973; 18: 1
        • Block W.D.
        • Jarrett K.J.
        • Leoine B.
        Use of a single color reagent to improve the automated determination of serum total cholesterol.
        in: Automation in Analytical Chemistry. Vol. 1. Medical Inc, New York, N.Y1965: 345-347
        • Carlson L.A.
        Determination of serum triglycerides.
        J. Atheroscler. Res. 1963; 3: 334
        • Kessler G.
        • Lederer H.
        Fluorimetric measurement of triglycerides.
        in: Automation in Analytical Chemistry. Vol. 1. Medical Inc, New York, N.Y1965: 341-344
        • Beaumont J.L.
        • Carlson L.A.
        • Cooper G.R.
        • Fejfar Z.
        • Fredrickson D.S.
        • Strasser T.
        Classification of hyperlipidaemias and hyperlipoproteinaemias.
        Bull. Wld. Hlth. Org. 1970; 43: 891
        • Ikkos D.
        • Luft R.
        On the intravenous glucose tolerance test.
        Acta Endocrinol. (Kb.). 1957; 25: 312
        • Boberg J.
        • Carlson L.A.
        • Hallberg D.
        Application of a new intravenous fat tolerance test in the study of hypertriglyceridaemia in man.
        J. Atheroscler. Res. 1969; 9: 159
        • Boberg J.
        • Carlson L.A.
        • Fröberg S.
        • Olsson A.
        • Orö L.
        • Rössner S.
        Effects Of chronic treatment with nicotinic acid on intravenous fat tolerance and postheparin lipoprotein lipase activity in man.
        in: Gey K.F. Carlson L.A. Metabolic Effects of Nicotinic Acid and its Derivatives. Hans Huber, Bern1971: 466
        • Carlson L.A.
        • Rössner S.
        A methodological study on an intravenous fat tolerance test with the Intralipid® emulsion.
        Scand. J. Clin. Lab. Invest. 1972; 29: 271
        • Snedecor G.W.
        Statistical Methods.
        The Iowa State University Press, Ames, Iowa1961
        • Brattsand R.
        • et al.
        Influence of nicotinic acid on postprandial hyperlipemia and lipoprotein lipase activity in the rat.
        in: Gey K.F. Carlson L.A. Metabolic Effects of Nicotinic Acid and its Derivatives. Hans Huber, Bern1971: 525
        • Fröberg S.O.
        • Boberg J.
        • Carlson L.A.
        • Ericson M.
        Effect of nicotinic acid oil the diurnal variation of plasma levels of glucose, free fatty acids, triglycerides and cholesterol and of urinary excretion of catecholamines.
        in: Gey K.F. Carlson L.A. Metabolic Effects of Nicotinic Acid and its Derivatives. Huber, Bern1971: 167
        • Carlson L.A.
        • Orö L.
        Acute effect of a sustained release pyridyl carbinol preparation, Ronicol Retard®, on plasma free fatty acids.
        Acta Med. Scand. 1969; 186: 337
        • Gaut Z.N.
        • Pocelinko R.
        • Solomon H.M.
        • Thomas G.B.
        Oral glucose tolerance, plasma insulin, and uric acid excretion in man during chronic administration of nicotinic acid.
        Metabolism. 1971; 20: 1031
      1. Olsson, A. G., Orö, L. and Rössner, S., Clinical and metabolic effects of pentaerythritoltetranicotinate in combination with cholesolvin or clofibrate, In manuscript.